Allogeneic Nerve Grafting

Phase 3

EEndeavor Health

Allogeneic Nerve Grafting is one of 4 therapeutic programs targeting Breast Reconstruction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Breast ReconstructionNot yet recruiting

Breast ReconstructionPhase 3

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Breast Reconstruction

#DrugCompanyPhaseTrials

Rogaine

Pfizer

Phase 1

1 2

Allogeneic Nerve Grafting

EEndeavor Health

Phase 3

1 3

Bupivicaine

TThomas Jefferson University

Preclinical

1 4

Fibrin Sealant

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

ApprovedNot yet recruiting

Breast Reconstruction

NCT07819357

Clinical

Trials by Indication[1]

Breast Reconstruction1 trial

A Randomized, Blinded, Within-Subject Trial of Allogeneic Nerve Grafting After Bilateral Nipple-Sparing Mastectomy With Implant-Based Reconstruction

Not yet recruiting·EEndeavor Health·Approved·NCT07819357·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Allogeneic Nerve Grafting. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Allogeneic Nerve Grafting. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Endeavor Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: EEndeavor Health

Allogeneic Nerve Grafting

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Breast Reconstruction1 trial

References

Drug Info

Quick Facts

Related News